vTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a note issued to investors on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners assumed coverage on shares of vTv Therapeutics in a research report on Monday, December 9th. They set a “buy” rating and a $35.00 price objective for the company.

vTv Therapeutics Stock Up 6.8 %

NASDAQ:VTVT opened at $19.66 on Monday. The business’s 50-day moving average price is $16.07 and its 200 day moving average price is $15.31. vTv Therapeutics has a 52-week low of $12.12 and a 52-week high of $30.99. The firm has a market cap of $62.72 million, a P/E ratio of -4.34 and a beta of 0.73.

Hedge Funds Weigh In On vTv Therapeutics

Several hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC increased its position in vTv Therapeutics by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock worth $158,000 after buying an additional 1,327 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in shares of vTv Therapeutics in the fourth quarter valued at about $25,000. Finally, FMR LLC bought a new stake in shares of vTv Therapeutics in the third quarter valued at about $2,402,000. 17.51% of the stock is owned by institutional investors and hedge funds.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.